Skip to main content
Signal8

Rapid Therapeutic Science Laboratories, Inc. (RTSL)

Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.

Sector: Medical - Pharmaceuticals

Industry: Medical - Pharmaceuticals

Rapid Therapeutic Science Laboratories, Inc. logo

Rapid Therapeutic Science Laboratories, Inc.

OTC:RTSLHealthcare
$0.0001
CLOSED
Mkt Cap$883
EV-
Float3.69M
O/S8.83M
VOL213 sh
$ Vol$0
RVOL0.41×
Inst Own-
Net Cash/Sh-
Dilution
FormDescription
    Rapid Therapeutic Science Laboratories (RTSL) SEC Filings | Signal8